DPPC-d9

• UNSPSC Description:

  DPPC-d9 is the deuterium labeled DPPC. DPPC (129Y83) is a zwitterionic phosphoglyceride that can be used for the preparation of liposomal monolayers[1]. DPPC-liposome serves effectively as a delivery vehicle for inducing immune responses against GSL antigen in mice[2].

• Target Antigen:

  Endogenous Metabolite

• Type:

  Isotope-Labeled Compounds

• Related Pathways:

  Metabolic Enzyme/Protease

• Field of Research:

  Others

• Purity:

  95.0

• Solubility:

  10 mM in DMSO

• Smiles:

  O=C(OC[C@H](COP(OCC[N+](C)(C)C)([O-])=O)OC(CCCCCCCCCCCCCCC)=O)CCCCCCCCCCCC([2H])(C([2H])(C([2H])(C([2H])([2H])[2H])[2H])[2H])[2H]

• Molecular Weight:

  743.09

• References & Citations:

  [1]Russak EM, et al. Impact of Deuterium Substitution on the Pharmacokinetics of Pharmaceuticals. Ann Pharmacother. 2019;53(2):211-216. |[2]Miller AD. Delivery of RNAi therapeutics: work in progress. Expert Rev Med Devices. 2013 Nov;10(6):781-811.|[3]Akiko Uemura, et al. Induction of immune responses against glycosphingolipid antigens: comparison of antibody responses in mice immunized with antigen associated with liposomes prepared from various phospholipids. J Vet Med Sci. 2005 Dec;67(12):1197-201.

• Shipping Conditions:

  Blue Ice

• Storage Conditions:

  -20°C, 3 years (Powder)

• Clinical Information:

  No Development Reported